Patent strategy in pharmaceutical industry : are additional patents valuable? /

Saved in:

Bibliographic Details
Author / Creator:	Donghi, Monica, author.
Edition:	1. Auflage.
Imprint:	Baden-Baden : Nomos, 2014.
Description:	1 electronic resource (84 pages ).
Language:	English
Series:	MIPLC studies ; volume 20 MIPLC studies ; volume 20.
Subject:	Drugs -- Patents -- Economic aspects -- European Union countries. Patent medicines -- Law and legislation -- European Union countries. Patent medicines -- European Union countries -- Case studies. Patent medicines. Patent medicines -- Law and legislation. European Union countries. Case studies.
Format:	E-Resource Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/11736106

Hidden Bibliographic Details
ISBN:	3848709910 9783848709915 9783845251288 384525128X
Digital file characteristics:	data file
Notes:	Originally presented as author's thesis (LL.M.)--Munich Intellectual Property Law Center, 2012. Includes bibliographical references (pages 77-84). Description based on print version record; resource not viewed.
Summary:	Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20.
Other form:	Print version: Patent strategy in pharmaceutical industry Baden-Baden : Nomos, 2014. 9783848709915

Table of Contents:

Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry
The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.

Similar Items